ReNeuron Group plc Total Voting Rights (4683Y)
02 January 2020 - 6:00PM
UK Regulatory
TIDMRENE
RNS Number : 4683Y
ReNeuron Group plc
02 January 2020
2 January 2020 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Total Voting Rights
At 31 December 2019, the Company had 31,833,770 ordinary shares
in issue, each carrying one voting right. This follows the issue of
1,500 new shares arising from the exercise of options by staff,
such shares having been admitted under the Company's existing block
listing arrangement.
As the Company holds no ordinary shares in treasury, the figure
of 31,833,770 may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Tilly Abraham
Argot Partners (US) +1 212 600 1902
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
N+1 Singer +44 (0) 20 7496 3000
Aubrey Powell, James Moat, Mia Gardner (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis
pigmentosa, and for disability as a result of stroke. ReNeuron is
also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRUPUCCGUPUPUG
(END) Dow Jones Newswires
January 02, 2020 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024
